Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events

被引：4
|
作者：
Reid, Pankti [1 ]
Sparks, Jeffrey A. [2 ]
Bass, Anne R. [3 ,4 ]
机构：
[1] Univ Chicago, Med Ctr, Div Rheumatol, Chicago, IL USA
[2] Brigham & Womens Hosp, Div Rheumatol Inflammat & Immun, Boston, MA USA
[3] Hosp Special Surg, Div Rheumatol, Weill Cornell Med, New York, NY USA
[4] Hosp Special Surg, Weill Cornell Med, 535 E 70th St, New York, NY 10021 USA
来源：
JAMA ONCOLOGY | 2023年 / 9卷 / 05期
关键词：
D O I：
10.1001/jamaoncol.2023.0100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：723 / 724
页数：2
相关论文
共 50 条
  • [1] Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply
    van Not, Olivier J.
    Verheijden, Rik J.
    Suijkerbuijk, Karijn P. M.
    [J]. JAMA ONCOLOGY, 2023, 9 (05) : 724 - 724
  • [2] Immune-related adverse events in urothelial cancer patients: Adjustment for immortal time bias
    Otsuka, Hikari
    Kita, Yuki
    Ito, Katsuhiro
    Sano, Takeshi
    Inokuchi, Junichi
    Tomida, Ryotaro
    Takahashi, Atsushi
    Matsumoto, Kazumasa
    Kurahashi, Ryoma
    Ozaki, Yu
    Uegaki, Masayuki
    Maruyama, Satoru
    Mukai, Shoichiro
    Tsutsumi, Masakazu
    Kawahara, Takashi
    Segawa, Takehiko
    Kitamura, Hiroshi
    Morita, Satoshi
    Kobayashi, Takashi
    [J]. CANCER SCIENCE, 2022, 113 (11) : 3912 - 3921
  • [3] Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of Treatment
    Fujiwara, Yu
    Cortellini, Alessio
    Naqash, Abdul Rafeh
    [J]. JAMA DERMATOLOGY, 2024,
  • [4] Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors
    Manne, Ashish
    Mulekar, Madhuri S.
    Escobar, Daisy E.
    Alsayed, Alhareth
    Sharma, Gaurav
    Prodduturvar, Pranitha
    Khushman, Moh'd
    Howard, John Harrison
    Gilbert, Robert
    Alkharabsheh, Omar
    [J]. JOURNAL OF CLINICAL MEDICINE RESEARCH-CANADA, 2021, 13 (05): : 268 - 275
  • [5] Unravelling the Acute, Chronic and Steroid-Refractory Management of High-Grade Neurological Immune-Related Adverse Events: A Call to Action
    Malvaso, Antonio
    Giglio, Pierpaolo
    Diamanti, Luca
    Gastaldi, Matteo
    Vegezzi, Elisa
    Pace, Andrea
    Bini, Paola
    Marchioni, Enrico
    [J]. BRAIN SCIENCES, 2024, 14 (08)
  • [6] Immune-related adverse events after a single dose of pembrolizumab
    Vos, Hanne
    Lambein, Kathleen
    Wildiers, Hans
    Punie, Kevin
    Smeets, Ann
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 148 : 92 - 94
  • [7] Association of Survival With Immune-Related Adverse Events-Time to Consider the Duration of Treatment-Reply
    Du, Yaxin
    Da, Meihong
    Wang, Fei
    [J]. JAMA DERMATOLOGY, 2024,
  • [8] Multiple high-grade and rare immune-related adverse events in a colon cancer patient with genomic and cytokine profiling
    Tyan, Kevin
    Abu-Shawer, Osama
    Baginska, Joanna
    Severgnini, Mariano
    Manos, Michael
    Vaitkevicius, Henrikas
    Grover, Shilpa
    Hodi, F. Stephen
    Rahma, Osama E.
    [J]. IMMUNOTHERAPY, 2022, 14 (11) : 843 - 850
  • [9] Management of Steroid-Refractory Immune-Related Adverse Events
    Watson, Marley L.
    Beardslee, Tyler
    [J]. ONCOLOGY-NEW YORK, 2019, 33 (08): : 304 - 306
  • [10] Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis
    Washino, Satoshi
    Shirotake, Suguru
    Takeshita, Hideki
    Inoue, Masaharu
    Miura, Yuji
    Hyodo, Yoji
    Kagawa, Makoto
    Izumi, Keita
    Oyama, Masafumi
    Kawakami, Satoru
    Saito, Kazutaka
    Matsuoka, Yoh
    Taniuchi, Satsuki
    Shintani, Ayumi
    Miyagawa, Tomoaki
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (12) : 1651 - 1658
12345